Hemlibra Sales Driving Global Bispecific Antibodies Market
Hemlibra Accounted For More Than 85% Of Global Bispecific Antibodies Sales In 2021
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Detailed Market Sales & Trends Insight
- Quarterly & Yearly Sales Insight Of Approved Antibodies Till Q1 2022
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
Hemlibra is bispecific antibody which restores the hemostatic process and indicated for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patient’s ages newborn and older with hemophilia A with or without factor VIII inhibitors. It mainly acts by mimicking the action of clotting Factor VIIIa (Activated VIII) and hence maintains the normal process of blood clotting. Factor VIII lays an important role in the process of blood coagulation as it activates several other clotting factors.
In 2021 Hemlibra Accounted For More Than 85% Of Global Bispecific Antibodies Sales
It is product of Roche which gained approval in 2018. The regulatory bodies have approved Hemlibra as preventive treatment to minimize the frequency of bleeding episodes in children and adults, newborn and older, with hemophilia A with or without VIII inhibitors. It is administered subcutaneously (under the skin) and only once weekly, every two weeks or every four weeks. Owing to their ability to specifically target two different factors which are involved in clotting cascade, the drug has demonstrated significant blood control.
In 2021, Hemlibra accounted for about 85% share in the global market which is mainly attributed to surge in cases of hemophilia A and its encouraging response in the management of disease. For instance in 2021, the global sales of the drug have significantly increased by 40% in comparison to last year. Amid region, US is dominating the market which is attributed to rising awareness about the availability of bispecific antibody and presence of favorable reimbursement policies in the region. Genetech has developed Hemlibra Co-pay program which helps eligible patients to reduce their out-of pocket cost in their course of treatment. The eligible patient should not be government beneficiary and/or participant in a federal or state-funded health insurance program. The eligible patient in hemlibra co-pay program as low as US$ 5 per treatment to a maximum benefit of US$ 15,000 per year in drug co-pay costs.
Apart from Hemlibra, three other bispecific antibody constructs including Blincyto, Rybrevant, and Vabysmo have also entered the global market. Rybrevant and Vbysmo has reently entered the global market and are expected to follow similar sales pattern as Hemlibra and Blincyto, which will drive the growth of market during the forecast period. Till 2021, it has been demonstrated that the cumulative sales of bispecific antibodies were about US$ 9 Billion, thus indicating positive future of these antibody constructs in pharmaceutical market. The promising response of these drugs has also gained interest from pharmaceutical giants to actively invest in research and development activities related to bispecific antibodies.
As per our report findings, the global bispecific antibody market is expected to surpass US$ 20 Billion by 2028. It is expected that about 3-5 bispecific antibodies will gain approval in the market. For instance in 2022, European Medicine Agency has adopted a positive opinion on the conditional marketing approval of mosunetuzumab (Lunsumio). Mosunetuzumab developed Biogen is novel CD20xCD3 T-cell engaging bispecific antibody in development and is indicated for B-cell non-Hodgkin’s lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). In addition to this, rise in prevalence of chronic diseases, unmet need of targeted therapies, and ability of bispecific antibodies to target the multifactorial nature of chronic diseases will also drive the growth of market during the forecast period.
Our report provides comprehensive analysis on globally approved bispecific antibodies therapeutics along with their commercial information including patent, price, dosage, and quarterly and yearly sales till Q1 2022. Apart from this, the report also provides in-depth analysis on ongoing clinical trials in the market. The major players mentioned in the report include Amgen, Roche, Emergent Biosolution, Jounce Therapeutics, Eli Lilly, AstraZeneca, Regenron Pharmaceuticals, Genmab, and others.